Reference

Process for forming amorphous azithromycin particles

All Rights Reserved. Process for forming amorphous azithromycin particles. Lyon, David Keith; Shalaev, Evgenyi (Pfizer Products Inc., USA). PCT Int. Appl. WO 2007007148 A1 18 Jan 2007, 24pp.Some commonly used reagents like 83905-01-5 and 117772-70-0 are used in this experiment. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-IB1859 3 Jul 2006. PRIORITY: US 2005-699984P 14 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) The present invention relates to a process of forming amorphous azithromycin comprises the steps of forming a soln. comprising azithromycin and a solvent, atomizing the soln., followed by evapg. at least a portion of the solvent from the soln. to form amorphous azithromycin. To test the phys. stability of amorphous azithromycin prepd. by a solvent process, samples were stored at 40° and 75% RH for 5 mo. Essentially all of the azithromycin was amorphous after storage for 5 mo at these conditions. .